Art Krieg

Art Krieg, a pioneering physician-scientist and CEO of Zola Therapeutics, discusses groundbreaking work in cancer immunotherapy. He shares how his early medical experiences shaped his interest in immunology and led to the discovery of immune-stimulatory CpG DNA. Art recounts his journey through clinical trials, exploring the balance between successes and setbacks. He explains Zola's innovative approach using synthetic retroviral particles to activate immune responses, all while emphasizing the importance of learning from veterinary studies to inform human applications.